Named as a key player in 33 of our reports, across 33 regions and countries.
Our reports that name Alere Inc. (now part of Abbott) as a key player, by category and place.
Markets where they are a key player. Each opens the market's statistics for every place we cover.
None of their markets match.
Our newest markets with them as a key player. Each covers 2024 history, a 2025 base year and forecasts to 2034.
Named as key players in the same markets as Alere Inc. (now part of Abbott) (number of shared markets).
Erba Mannheim (Transasia Bio-Medicals Ltd.)1 shared market
Instrumentation Laboratory1 shared market
Medica Corporation1 shared market
Nova Biomedical1 shared market
Roche Diagnostics1 shared market
Siemens Healthineers1 shared market
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
0 active studies led by Alere Inc. (now part of Abbott), of 5 in all
Source: ClinicalTrials.gov, Studies with Alere Inc. (now part of Abbott) (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
3 510(k) clearances and PMA approvals since 2015
Source: FDA 510(k) and PMA databases, 510(k) clearances, and PMA approvals or changes, since 2015; newest shown. Retrieved 13 Nov 2026.
The topics of the markets Alere Inc. (now part of Abbott) is in.
Stories on the topics Alere Inc. (now part of Abbott) works in.
Skin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Read
More than half of deaths in low- and middle-income countries come from conditions emergency care could treat…
Read
TB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade…
ReadSearch all reports for Alere Inc. (now part of Abbott) All companies